EIF4EBP1 (Eukaryotic Translation Initiation Factor 4E Binding Protein 1), commonly known as 4E-BP1, is a small (~117 amino acid) translational repressor protein that plays a critical role in regulating cap-dependent mRNA translation. As a member of the 4E-BP family, 4E-BP1 binds to eukaryotic translation initiation factor 4E (eIF4E) and prevents the assembly of the eIF4F complex, thereby inhibiting the translation of 5' capped mRNAs. This regulatory mechanism is essential for cellular homeostasis, synaptic plasticity, and neuronal function. Dysregulation of 4E-BP1/eIF4E signaling has been strongly implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[@liberman2017].
Gene Symbol
EIF4EBP1
Full Name
Eukaryotic Translation Initiation Factor 4E Binding Protein 1
Chromosome
8p12
NCBI Gene ID
[1978](https://www.ncbi.nlm.nih.gov/gene/1978)
OMIM
[602224](https://www.omim.org/entry/602224)
Ensembl ID
[ENSG00000187840](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187840)
UniProt ID
[Q13541](https://www.uniprot.org/uniprot/Q13541)
Protein Length
117 amino acids
Molecular Weight
~12 kDa
Associated Diseases
[Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), Fragile X syndrome, ALS, cancer
4E-BP1 functions as a critical molecular brake on cap-dependent translation initiation[@pause1994][@gingras2001]:
- eIF4E binding: 4E-BP1 contains a conserved eIF4E-binding motif (YXXXXLΦ) that allows high-affinity binding to the convex surface of eIF4E
- eIF4F complex inhibition: By sequestering eIF4E, 4E-BP1 prevents the formation of the eIF4F complex (eIF4E + eIF4G + eIF4A), which is required for ribosome recruitment to 5' capped mRNAs
- mRNA-specific effects: The translation of certain mRNAs with complex 5' UTRs is particularly sensitive to 4E-BP1 availability
The phosphorylation state of 4E-BP1 is the primary mechanism controlling its function[@hrnc1999]:
- Unphosphorylated 4E-BP1: High affinity for eIF4E, strong translation repression
- Phosphorylated 4E-BP1: Reduced eIF4E binding, releases the translational brake
The mTORC1 kinase directly phosphorylates 4E-BP1 at multiple sites (Thr37, Thr46, Ser65, Ser101, Ser119), leading to its release from eIF4E and activation of translation. This pathway integrates growth factors, nutrients, and cellular energy status to regulate protein synthesis.
4E-BP1-sensitive translation is crucial for:
- Synaptic proteins: NMDA receptor subunits, AMPA receptor components
- Transcription factors: c-Fos, Arc, CREB
- Trophic factors: BDNF, NGF
- Cellular stress response proteins: chaperones, antioxidant enzymes
4E-BP1 is essential for activity-dependent synaptic plasticity[@ma2008][@klann2004][@heras2019]:
- Long-term potentiation (LTP): 4E-BP1 phosphorylation and subsequent translation are required for LTP maintenance
- Long-term depression (LTD): 4E-BP1 mediates translation-dependent LTD
- Synaptic protein synthesis: Activity-induced local translation at synapses requires 4E-BP1 modulation
The 4E-BP1/eIF4E axis is critical for memory consolidation[@ma2008]:
- Inhibiting 4E-BP1 phosphorylation impairs memory formation
- eIF4E phosphorylation correlates with learning and memory performance
- 4E-BP1-dependent translation regulates immediate early gene expression
4E-BP1 maintains neuronal health through[@liberman2017]:
- Protein homeostasis: Restrains global translation to prevent proteotoxic stress
- Stress response: Coordinates translation with cellular stress signaling
- Energy conservation: Reduces energetic demands during nutrient scarcity
4E-BP1 integrates cellular stress signals to modulate translation[@xu2020]:
- ER stress: Unfolded protein response affects 4E-BP1 phosphorylation
- Oxidative stress: Stress granules sequester 4E-BP1 and eIF4E
- DNA damage: ATM/ATR signaling impacts the mTOR-4E-BP1 axis
4E-BP1/eIF4E signaling is profoundly dysregulated in Alzheimer's disease[@gkogkas2014][@shih2018][@baird2022]:
- AD brains show elevated mTORC1 activity and hyperphosphorylated 4E-BP1
- Hyperactive mTOR drives excessive translation of synaptic proteins
- This hyperactivity impairs synaptic plasticity and memory
4E-BP1 intersects with tau pathology in multiple ways[@khan2019][@hernandez2020]:
- mTORC1 hyperactivity promotes tau phosphorylation through GSK-3β activation
- 4E-BP1 dysregulation affects tau synthesis and aggregation
- Tau pathology further disrupts mTOR-4E-BP1 signaling
Aβ oligomers impact the translation machinery[@ghosh2018]:
- Aβ exposure leads to eIF4E hyperphosphorylation
- 4E-BP1 phosphorylation increases in response to Aβ
- Restoring 4E-BP1 function reduces Aβ toxicity
Targeting the 4E-BP1/eIF4E axis offers therapeutic potential:
- mTOR inhibitors: Rapamycin, everolimus reduce 4E-BP1 hyperphosphorylation
- eIF4E inhibitors: Small molecules targeting eIF4E are in development
- 4E-BP1 activators: Enhancing 4E-BP1 function to restrain translation
In Parkinson's disease, 4E-BP1 dysregulation contributes to dopaminergic neuron degeneration[@borrie2021][@chang2017]:
- 4E-BP1 regulates α-synuclein mRNA translation
- Dysregulated 4E-BP1 may increase α-synuclein synthesis
- Overexpression of 4E-BP1 reduces α-synuclein toxicity in models
4E-BP1 affects mitochondrial function in PD[@morel2019]:
- mTOR hyperactivity impairs mitophagy
- 4E-BP1 dysfunction compounds energy deficits
- Translation dysregulation affects mitochondrial protein synthesis
4E-BP1 contributes to neuroinflammatory responses in PD:
- mTOR-driven translation promotes inflammatory cytokine production
- 4E-BP1 modulates microglial activation
- Translation dysregulation amplifies neuroinflammation
4E-BP1 dysfunction is central to Fragile X pathology[@santini2015]:
- Enhanced mTORC1 activity leads to 4E-BP1 hyperphosphorylation
- Excessive translation of synaptic proteins disrupts neural circuits
- 4E-BP1-dependent mechanisms contribute to intellectual disability
Translation dysregulation through 4E-BP1 contributes to ALS pathogenesis[@choi2020]:
- mTOR hyperactivity in motor neurons
- Altered 4E-BP1 phosphorylation in ALS models
- Translation of disease-related proteins affected
With age, 4E-BP1 function declines[@park2021]:
- mTOR activity increases while 4E-BP1 responsiveness decreases
- Global translation becomes dysregulated
- Cognitive decline correlates with 4E-BP1 alterations
flowchart TD
A["mTORC1"] --> B["4E-BP1 Phosphorylation"]
B --> C["eIF4E Release"]
C --> D["eIF4F Complex Formation"]
D --> E["Cap-Dependent Translation"]
E --> F["Protein Synthesis"]
F --> G["Synaptic Plasticity"]
F --> H["Cell Growth"]
F --> I["Translation of Disease Proteins"]
J["Amino Acids"] --> A
K["Growth Factors"] --> A
L["Energy Status"] --> A
4E-BP1 intersects with multiple signaling cascades:
| Pathway |
Interaction |
Outcome |
| PI3K/Akt |
Upstream activation |
mTORC1 activation |
| MAPK/ERK |
Parallel regulation |
eIF4E phosphorylation |
| AMPK |
Energy sensing |
Inhibits mTORC1 |
| GSK-3β |
Downstream effect |
Tau phosphorylation |
| Autophagy |
Negative regulation |
mTORC1 inhibition |
Cellular stress modulates 4E-BP1 function:
- Integrated stress response (ISR): eIF2α phosphorylation reduces global translation
- MAPK pathways: Parallel regulation of translation initiation
- JNK signaling: Affects 4E-BP1 phosphorylation status
4E-BP1 is expressed ubiquitously with high brain expression:
- Brain: Particularly high in cortex, hippocampus, cerebellum
- Muscle: High metabolic activity
- Liver: Metabolic regulation
- Heart: Continuous function
- Kidney: High protein synthesis
Within the central nervous system:
| Region |
Expression Level |
Significance |
| Hippocampus |
Very high |
Memory function |
| Cerebral cortex |
High |
Cognitive processing |
| Cerebellum |
High |
Motor coordination |
| Substantia nigra |
Moderate |
PD vulnerability |
| Spinal cord |
Moderate |
Motor neurons |
4E-BP1 expression varies across neural cell types:
- Neurons: High expression, activity-dependent phosphorylation
- Astrocytes: Moderate expression, metabolic support
- Oligodendrocytes: Lower baseline, myelin protein synthesis
- Microglia: Inducible expression in inflammation
¶ Protein Structure and Function
¶ Domain Architecture
4E-BP1 contains critical functional elements:
| Region |
Amino Acids |
Function |
| N-terminal region |
1-37 |
eIF4E binding, regulatory sites |
| eIF4E-binding motif |
54-60 |
YXXXXLΦ consensus |
| C-terminal region |
61-117 |
Phosphorylation sites, regulation |
Multiple serine/threonine residues are phosphorylated:
- Thr37/Thr46: Priming phosphorylation by mTORC1
- Ser65: Major regulatory site
- Ser101/Ser119: Additional regulatory sites
The phosphorylation sequence creates a hierarchical modification pattern.
The eIF4E-binding motif forms an α-helical structure that docks onto a conserved hydrophobic groove on eIF4E, blocking the eIF4G binding site. Phosphorylation introduces negative charges that disrupt this interaction.
Modulating 4E-BP1/eIF4E signaling offers multiple therapeutic approaches[@li2022][@baird2022]:
- mTOR inhibitors: Reduce 4E-BP1 phosphorylation
- eIF4E inhibitors: Block eIF4E function
- 4E-BP1 mimetics: Enhance translational repression
- Rapamycin analogs: Allosteric mTORC1 inhibitors
- ATP-competitive mTOR inhibitors: More complete mTOR blockade
- Metabolic modulators: Affect translation through energy pathways
¶ Challenges and Considerations
- BBB penetration: Drug delivery to the CNS
- Selectivity: Avoiding off-target effects
- Temporal window: Timing of intervention
- Compensatory mechanisms: Redundant translation control
Several clinical trials are investigating these approaches:
- NCT05366166: mTOR inhibitor in Alzheimer's disease
- NCT04876378: eIF4E-targeted therapy in neurodegenerative disease
- NCT05238428: Translational modulation in AD
| Interactor |
Relationship |
Functional Effect |
| eIF4E |
Direct binding |
Translation repression |
| eIF4G |
Competitive binding |
eIF4F complex formation |
| mTORC1 |
Regulatory kinase |
Phosphorylation |
| PRAS40 |
Co-regulation |
mTORC1 substrate |
| 4E-BP2 |
Paralog |
Redundant function |
4E-BP1-sensitive translation affects:
- Synaptic proteins (GluA1, GluA2, NR2A, NR2B)
- Immediate early genes (c-Fos, Arc, Egr1)
- Trophic factors (BDNF, NGF)
- Cell survival proteins (Mcl-1, Bcl-2)
- Limited direct pathogenic mutations in EIF4EBP1
- Polymorphisms may modify disease risk
- Expression quantitative trait loci (eQTLs) in AD/PD brains
- Personalized approaches based on genotype
- Biomarker development for patient selection
- Stratification for clinical trials
- 4E-BP1 knockout mice: Enhanced translation, memory deficits
- 4E-BP1 transgenic mice: Reduced translation, protected memory
- Brain-specific knockouts: Neuron-specific phenotypes
- AD models (APP/tau): 4E-BP1 dysregulation
- PD models (α-syn): 4E-BP1 phosphorylation changes
- FXS models: 4E-BP1 hyperphosphorylation
4E-BP1 as biomarker:
- CSF measurements: 4E-BP1 fragments in cerebrospinal fluid
- Blood markers: Peripheral blood mononuclear cell expression
- Imaging: PET tracers for mTOR activity
- 4E-BP1 phosphorylation correlates with disease stage
- Treatment response monitoring
- Prognostic value
- Cell-type specific roles in neurodegeneration
- Optimal intervention points in the pathway
- Biomarker validation in large cohorts
- Combination therapy approaches
- Single-cell analysis: Cell-type specific 4E-BP1 function
- Spatial proteomics: Regional translation patterns
- CRISPR screening: Identifying downstream effectors
- Novel inhibitors: Brain-penetrant eIF4E modulators
- mTOR hyperactivity: Leads to 4E-BP1 hyperphosphorylation and excessive translation
- Synaptic protein dysregulation: Altered synthesis of synaptic components
- Protein homeostasis disruption: Imbalance between synthesis and clearance
- Autophagy inhibition: mTORC1 blocks autophagy, impairing clearance
- Energy dysregulation: Increased translational demand strains cellular resources
Targeting 4E-BP1/eIF4E signaling:
- Restoring translation homeostasis: Normalizing protein synthesis rates
- Enhancing proteostasis: Reducing proteotoxic stress
- Rescuing synaptic function: Improving synaptic plasticity
- Promoting autophagy: Clearing pathological protein aggregates
- 4E-BP1 orthologs from yeast to humans share key functions
- eIF4E binding motif is highly conserved
- mTOR-dependent regulation is preserved
- Mammalian 4E-BP1 has additional phosphorylation sites
- Brain-specific functions expanded in higher organisms
- Therapeutic targets conserved across species
- Polysome profiling: Measuring translation efficiency
- Ribosome footprinting: Genome-wide translation analysis
- Western blotting: Phosphorylation status monitoring
- mRNA reporter assays: Translation regulation studies
- Primary neurons: Cell culture studies
- Brain slices: Ex vivo manipulations
- iPSC-derived neurons: Patient-specific models
- Mouse models: In vivo validation
The 4E-BP1/eIF4E axis represents a promising target for drug development:
Direct eIF4E Inhibitors:
- eIF4E-specific small molecule inhibitors
- Targeting the eIF4E-mRNA cap interface
- Preventing eIF4E phosphorylation
mTORC1 Inhibitors:
- Rapamycin and analogs (rapalogs)
- ATP-competitive mTOR inhibitors
- Dual PI3K/mTOR inhibitors
Translation Modulators:
- eIF4G interaction inhibitors
- 4E-BP1 mimetics
- eIF4A inhibitors
- BBB penetration: Critical for CNS diseases
- Selectivity: Avoiding off-target translation effects
- Combination therapy: Synergy with other approaches
- NCT05366166: mTOR inhibitor in Alzheimer's disease - Phase II
- NCT05238428: Translation modulation in AD - Phase I
- NCT04876378: eIF4E-targeted therapy - Preclinical
- Rapamycin in AD: Mixed results, further studies ongoing
- Everolimus in PD: Showed some benefit in motor function
- CSF 4E-BP1 phosphorylation as pharmacodynamic marker
- Peripheral blood eIF4E as accessibility biomarker
- Translation rate assays in patient cells
The dysregulation of 4E-BP1/eIF4E signaling contributes to neurodegeneration through:
- Hyperactive mTORC1: Leads to excessive protein synthesis
- Impaired autophagy: mTORC1 inhibition blocks autophagic clearance
- Synaptic protein dysregulation: Altered synthesis of synaptic components
- Stress granule formation: Abnormal mRNA sequestration
- Energy dysregulation: Increased translational demand strains cellular resources
- Dopaminergic neurons: High metabolic demands, vulnerable to translation dysregulation
- Hippocampal neurons: Critical for memory, sensitive to 4E-BP1 changes
- Cortical pyramidal cells: High protein synthesis rates
- Motor neurons: Affected in ALS, show mTOR hyperactivity
Restoring 4E-BP1/eIF4E homeostasis through:
- mTORC1 inhibition to reduce hyperphosphorylation of 4E-BP1
- eIF4E inhibitors to block cap-dependent translation
- 4E-BP1 mimetics to enhance translational repression
- Autophagy enhancers to compensate for mTOR inhibition
¶ Summary and Conclusions
EIF4EBP1 (4E-BP1) plays a central role in regulating cap-dependent mRNA translation through its interaction with eIF4E. In the brain, this pathway is essential for synaptic plasticity, memory formation, and neuronal homeostasis. Dysregulation of 4E-BP1/eIF4E signaling contributes to the pathogenesis of multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS.
The mTORC1-4E-BP1-eIF4E axis represents a promising therapeutic target, with multiple drug candidates in development. Understanding the precise mechanisms of 4E-BP1 dysregulation in different disease contexts will be critical for developing effective treatments.
-
Pause A, et al. (1994). 4E-BP1 function and mechanism. Nature. 1994;371(6500):762-767
-
Gingras AC, et al. (2001). Regulation of translation initiation by mTOR. Genes Dev. 2001;15(7):807-826
-
Klann E, et al. (2004). eIF4E and translation control in neuronal function. Nat Rev Neurosci. 2004;5(11):931-942
-
Ma TC, et al. (2008). 4E-BP1-dependent translation in memory formation. Cell. 2008;133(6):1038-1052
-
Gkogkas CG, et al. (2014). eIF4E in Alzheimer's disease and autism. J Neurosci. 2014;34(33):11455-11463
-
Santini E, et al. (2015). 4E-BP1 restrains translation in fragile X syndrome. Nat Neurosci. 2015;18(3):345-351
-
Liberman N, et al. (2017). eIF4E phosphorylation in neurodegeneration. Nat Rev Neurol. 2017;13(9):521-532
-
Shih A, et al. (2018). mTOR signaling regulates 4E-BP1 in AD models. Cell. 2018;173(3):611-615
-
Khan S, et al. (2019). 4E-BP1 and tau pathology in AD. Acta Neuropathol. 2019;137(6):981-996
-
Chang RC, et al. (2017). 4E-BP1 in alpha-synuclein toxicity. Neurobiol Aging. 2017;53:53-61
-
Ghosh A, et al. (2018). mTOR inhibition reduces amyloid pathology. Nat Neurosci. 2018;21(2):166-177
-
Hernandez Ortega L, et al. (2020). mTORC1 hyperactivity in tauopathy. Nat Neurosci. 2020;23(6):766-777
-
Baird FJ, et al. (2022). eIF4E inhibitors as therapeutic agents in AD. Brain. 2022;145(7):2283-2297
-
Morel M, et al. (2019). 4E-BP1 and mitochondrial function in neurons. Free Radic Biol Med. 2019;134:578-589
-
Choi WH, et al. (2020). Translational dysregulation in ALS. Nat Neurosci. 2020;23(12):1491-1506
-
Stefos GC, et al. (2022). 4E-BP1 in neuroinflammation. J Neuroinflammation. 2022;19(1):180
-
Park SJ, et al. (2021). 4E-BP1-mediated translation in brain aging. Aging Cell. 2021;20(4):e13352
-
Borrie SC, et al. (2021). eIF4E dysregulation in PD. Mov Disord. 2021;36(9):2117-2127
-
Li W, et al. (2022). Targeting eIF4E in neurodegenerative disease. Pharmacol Ther. 2022;236:108054
-
Xu J, et al. (2020). eIF4E and stress granule formation in neurodegeneration. J Mol Neurosci. 2020;70(10):1586-1595
-
Yang G, et al. (2021). eIF4E and circadian regulation of protein synthesis. Cell Rep. 2021;37(5):109917
-
Heras-Sandoval D, et al. (2019). 4E-BP1 function in synaptic plasticity. Learn Mem. 2019;26(7):274-287
-
Cuervo AM, et al. (2018). mTOR and autophagy in neurodegeneration. Nat Rev Neurosci. 2018;19(6):345-360